Role of myeloid-derived suppressor cells in immune checkpoint inhibitor therapy in cancer

Combination anti-CXCR4 and anti-PD-1 immunotherapy provides survival benefit in glioblastoma through immune cell modulation of tumor microenvironment

(2019) Adela Wu et al.   JOURNAL OF NEURO-ONCOLOGY

Plasticity of myeloid-derived suppressor cells in cancer

(2018) Evgenii Tcyganov et al.   CURRENT OPINION IN IMMUNOLOGY

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

(2018) Leena Gandhi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cancer immunotherapy using checkpoint blockade

(2018) Antoni Ribas et al.   SCIENCE

Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors

(2018) Rebekka Weber et al.   Frontiers in Immunology

Inhibition of casein kinase 2 disrupts differentiation of myeloid cells in cancer and enhances the efficacy of immunotherapy in mice

(2018) Ayumi Hashimoto et al.   CANCER RESEARCH

The Ratio of Peripheral Regulatory T Cells to Lox-1+ Polymorphonuclear Myeloid-derived Suppressor Cells Predicts the Early Response to Anti–PD-1 Therapy in Patients with Non–Small Cell Lung Cancer

(2018) Hye Ryun Kim et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization

(2018) Miguel F. Sanmamed et al.   CELL

Cancer immunoediting and resistance to T cell-based immunotherapy

(2018) Jake S. O’Donnell et al.   Nature Reviews Clinical Oncology

Entinostat Converts Immune-Resistant Breast and Pancreatic Cancers into Checkpoint-Responsive Tumors by Reprogramming Tumor-Infiltrating MDSCs

(2018) Brian J. Christmas et al.   Cancer Immunology Research

Ipilimumab treatment decreases monocytic MDSCs and increases CD8 effector memory T cells in long-term survivors with advanced melanoma

(2017) Yago Pico de Coana et al.   Oncotarget

CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma

(2016) Colin W. Steele et al.   CANCER CELL

Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab

(2016) Benjamin Weide et al.   CLINICAL CANCER RESEARCH

Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab

(2016) A. Martens et al.   CLINICAL CANCER RESEARCH

Clinical Significance of Circulating CD33+CD11b+HLA-DR- Myeloid Cells in Patients with Stage IV Melanoma Treated with Ipilimumab

(2016) M. Sade-Feldman et al.   CLINICAL CANCER RESEARCH

Targeting Suppressive Myeloid Cells Potentiates Checkpoint Inhibitors to Control Spontaneous Neuroblastoma

(2016) Y. Mao et al.   CLINICAL CANCER RESEARCH

Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy

(2016) Takaaki Tokito et al.   EUROPEAN JOURNAL OF CANCER

Myeloid cells are required for PD-1/PD-L1 checkpoint activation and the establishment of an immunosuppressive environment in pancreatic cancer

(2016) Yaqing Zhang et al.   GUT

Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards

(2016) Vincenzo Bronte et al.   Nature Communications

Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab

(2016) J. Weber et al.   Cancer Immunology Research

Regulation of myeloid cells by activated T cells determines the efficacy of PD-1 blockade

(2016) Nina Eissler et al.   OncoImmunology

Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma

(2015) J. Bellmunt et al.   ANNALS OF ONCOLOGY

Characterization of PD-L1 Expression and Associated T-cell Infiltrates in Metastatic Melanoma Samples from Variable Anatomic Sites

(2015) H. M. Kluger et al.   CLINICAL CANCER RESEARCH

Myeloid Cells and Related Chronic Inflammatory Factors as Novel Predictive Markers in Melanoma Treatment with Ipilimumab

(2015) C. Gebhardt et al.   CLINICAL CANCER RESEARCH

Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected

(2015) Douglas Marvel et al.   JOURNAL OF CLINICAL INVESTIGATION

PD-L1 expression in nonclear-cell renal cell carcinoma

(2014) T. K. Choueiri et al.   ANNALS OF ONCOLOGY

Myeloid-derived suppressor cell heterogeneity in human cancers

(2014) Samantha Solito et al.   Annals of the New York Academy of Sciences

PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation

(2014) Muhammad Zaeem Noman et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Subsets of Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice

(2014) J.-I. Youn et al.   JOURNAL OF IMMUNOLOGY

PD-1 blockade induces responses by inhibiting adaptive immune resistance

(2014) Paul C. Tumeh et al.   NATURE

Disruption of CXCR2-Mediated MDSC Tumor Trafficking Enhances Anti-PD1 Efficacy

(2014) S. L. Highfill et al.   Science Translational Medicine

Myeloid-Derived Suppressor Cells in Cancer: Therapeutic, Predictive, and Prognostic Implications

(2014) C. Marcela Diaz-Montero et al.   SEMINARS IN ONCOLOGY

Myeloid derived suppressor and dendritic cell subsets are related to clinical outcome in prostate cancer patients treated with prostate GVAX and ipilimumab

(2014) Saskia JAM Santegoets et al.   Journal for ImmunoTherapy of Cancer

Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab

(2013) Christiane Meyer et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Clinical impact of programmed cell death ligand 1 expression in colorectal cancer

(2013) Raoul A. Droeser et al.   EUROPEAN JOURNAL OF CANCER

Epigenetic silencing of retinoblastoma gene regulates pathologic differentiation of myeloid cells in cancer

(2013) Je-In Youn et al.   NATURE IMMUNOLOGY

Immunoediting and Antigen Loss: Overcoming the Achilles Heel of Immunotherapy with Antigen Non-Specific Therapies

(2013) Arta Monir Monjazeb et al.   Frontiers in Oncology

Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion

(2011) R. D. Schreiber et al.   SCIENCE

Anti-inflammatory Triterpenoid Blocks Immune Suppressive Function of MDSCs and Improves Immune Response in Cancer

(2010) S. Nagaraj et al.   CLINICAL CANCER RESEARCH

The biology of myeloid-derived suppressor cells: The blessing and the curse of morphological and functional heterogeneity

(2010) Je-In Youn et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Myeloid-derived suppressor cell role in tumor-related inflammation

(2008) Luigi Dolcetti et al.   CANCER LETTERS